DMT and Ayahuasca: Legal Status in Australia
So let's be precise about that law first, before anything else.
DMT and ayahuasca under Australian law
N,N-Dimethyltryptamine , DMT , is a Schedule 9 prohibited substance under the Poisons Standard (the document that gives legislative force to Australia's drug scheduling system, maintained by the Therapeutic Goods Administration). Schedule 9 is the most restrictive scheduling category. Possession, use, manufacture, supply, and import of DMT are criminal offences under both Commonwealth and state/territory law. There is no general medical or research exemption that applies to the public.
Ayahuasca is a brewed preparation traditionally made from two plants; Banisteriopsis caapi (containing beta-carboline alkaloids including harmine and harmaline, which act as monoamine oxidase inhibitors) and Psychotria viridis or similar DMT-containing plants. Because the preparation contains DMT, it falls under the same Schedule 9 prohibition. The plants themselves occupy a grey area in some jurisdictions globally, but in Australia the presence of a prohibited substance in a preparation makes that preparation prohibited too. There is no carve-out for "traditional use" in the Poisons Standard.
The Australian Drug Foundation's drug information pages confirm DMT is illegal to possess or use in Australia, and that penalties vary by state and territory but can include imprisonment. Western Australia, where I'm based, carries some of the heavier penalties in the country for Schedule 9 substances.
What about the 2023 TGA rescheduling, does that change things for DMT?
This is the question I get most often, and the answer requires care. In February 2023, the TGA made a landmark decision to reschedule psilocybin (from Schedule 9 to Schedule 8 for specific therapeutic use) and MDMA (similarly) under very narrow conditions: only Authorised Prescribers approved by the TGA can prescribe these substances, only for specific patient populations, and only within a tightly governed clinical framework. That pathway is described further on the TGA's website and through the Special Access Scheme.
DMT and ayahuasca were not included in that rescheduling decision. They remain Schedule 9. No Authorised Prescriber pathway currently exists for DMT. No ARTG-registered product containing DMT exists in Australia. The 2023 decision does not extend to, imply, or create any general legalisation of psychedelic use, it is a narrow clinical carve-out for two specific substances, and even that is subject to strict prescriber registration and oversight.
Anyone representing otherwise; in a retreat context, online forum, or otherwise, is either misinformed or being deliberately misleading.
The chemistry: what DMT actually is
DMT is a tryptamine compound, structurally related to serotonin and the amino acid tryptophan. It is found endogenously in trace amounts in various mammals, including humans, though its physiological role remains a subject of genuine scientific debate rather than settled consensus. Exogenous DMT acts primarily as a full agonist at serotonin 5-HT2A receptors, which is the same receptor subtype implicated in the effects of other classical psychedelics like psilocin and LSD.
The pharmacokinetics of DMT are unusual. When taken orally as isolated DMT, the compound is rapidly broken down by monoamine oxidase enzymes in the gut wall and liver; this is sometimes called the first-pass metabolism effect, and virtually none reaches systemic circulation. This is precisely why ayahuasca combines DMT-containing plants with MAOI-containing plants: the beta-carbolines in Banisteriopsis caapi inhibit the enzymes that would otherwise degrade the DMT, allowing oral bioavailability. The bioavailability of DMT in an ayahuasca preparation is therefore substantially higher than it would be from the DMT source plant alone.
Smoked or vaporised DMT bypasses this issue entirely, producing very rapid onset and short duration of effect, typically reported in research literature as 5–20 minutes. Ayahuasca experiences are reported in the same literature as lasting several hours, owing to the slower oral absorption kinetics and the MAOI interaction.
I'll admit I found the pharmacokinetics literature genuinely fascinating when I first worked through it; the chemistry of why one route of administration produces a 15-minute experience and another produces a 4-hour one is elegantly explained by enzyme inhibition. But elegant chemistry does not mean safe or legal use, and the two should never be conflated.
Ayahuasca: cultural and historical context
Ayahuasca has been used in ceremonial and spiritual contexts by Indigenous Amazonian communities, including groups in Peru, Colombia, Brazil, and Ecuador, for centuries, likely longer. The term itself comes from the Quechua words for "vine" and "soul" or "dead." Use has traditionally been led by trained practitioners called curanderos or vegetalistas, within specific cultural frameworks that include preparatory practices, dietary protocols, and integration support.
Brazil is notable for having recognised the religious use of ayahuasca by certain syncretic churches (União do Vegetal and Santo Daime) since the 1980s. Peru has designated ayahuasca as part of its national cultural heritage. These regulatory recognitions exist within specific legal and cultural frameworks that do not translate to Australia.
Global tourism centred on ayahuasca ceremonies; particularly in Peru, has grown substantially over the past two decades, which is one reason Australians increasingly encounter information about it. Australian law, however, does not recognise overseas use as lawful upon return, and importing DMT-containing substances into Australia remains a Commonwealth offence under the Criminal Code Act 1995.
What the research landscape looks like
There is published research on DMT and ayahuasca. Some of it is quite interesting. But the peer-reviewed literature is substantially smaller, methodologically less advanced, and more preliminary than the online discourse suggests, and I reckon this gap between hype and evidence is a real problem for informed public understanding.
Research groups have published observational studies, small open-label trials, and neuroimaging work examining the acute and sub-acute effects of ayahuasca and DMT in human subjects. A 2016 study published in Psychological Medicine (Palhano-Fontes et al.) and a 2018 randomised controlled pilot in the same journal are frequently cited. These are small studies with significant methodological limitations; small sample sizes, no blinding in some cases, heterogeneous populations, short follow-up. The authors themselves note these limitations clearly. The same caution applies to DMT-specific neuroimaging research from groups at Imperial College London, which has produced genuinely novel findings about brain network activity but which represents early-stage mechanistic work rather than clinical evidence.
Reporting on this research in Australian media has sometimes been enthusiastic in ways the underlying papers do not support. None of this research changes the legal status of DMT in Australia. Controlled research on Schedule 9 substances requires both TGA and Human Research Ethics Committee approval, and any suggestion that research interest implies public access is incorrect.
Risks: what the evidence actually documents
DMT and ayahuasca carry documented risks that are not always prominent in popular coverage. These include:
- Cardiovascular effects: The beta-carboline MAOIs in ayahuasca produce clinically significant monoamine oxidase inhibition. This creates serious interaction risks with a wide range of medications (including common antidepressants, particularly SSRIs and SNRIs), certain foods, and other substances. Serotonin syndrome, a potentially life-threatening condition, has been reported in the context of ayahuasca use alongside serotonergic medications.
- Psychological risk: Acute adverse psychological reactions, including severe anxiety, dissociation, and psychotic episodes, have been documented in clinical and observational literature. Individuals with a personal or family history of psychotic disorders are generally identified in research protocols as exclusion criteria.
- Unregulated settings: Outside approved research contexts, there is no quality control, no screening, and no clinical oversight. The Australian Drug Foundation notes the particular risks of unregulated use.
- Legal consequences: Possession and use remain criminal offences. This is not a minor regulatory detail.
The Schedule 8 and Schedule 4 frameworks that govern other regulated substances in Australia exist precisely because risk assessment, prescriber training, and patient monitoring are considered necessary. DMT has not cleared those regulatory hurdles.
Where things stand, and what to watch
The TGA reviews the Poisons Standard periodically, and scheduling decisions can change; as the 2023 psilocybin/MDMA decision demonstrated. Any future rescheduling of DMT would need to follow the same evidence review and regulatory process: a delegate's review, public consultation, and a formal scheduling decision. There is no current public consultation on DMT rescheduling, and no approved clinical pathway.
For anyone genuinely interested in the science, the receptor pharmacology, the neuroimaging work, the historical anthropology, the academic literature is publicly accessible and worth reading carefully. That curiosity is legitimate. Acting on it in a way that breaks Australian law is a different matter entirely, with serious personal and legal consequences.
Sources
- Final decisions on amendments to the Poisons Standard, February 2023; Therapeutic Goods Administration (TGA)
- DMT drug facts, Australian Drug Foundation (ADF)
- Palhano-Fontes et al., Rapid antidepressant effects of ayahuasca: a randomised placebo-controlled trial (2018), National Library of Medicine / NCBI
- Authorised Prescribers; Therapeutic Goods Administration (TGA)
, Daniel Okoro, Psychedelic science & law writer
]]>Common questions
- Is ayahuasca legal in Australia?
- No. Ayahuasca contains DMT, which is a Schedule 9 prohibited substance under the Australian Poisons Standard. Possession, use, supply, and importation are criminal offences under both Commonwealth and state/territory law. There is no general exemption for ceremonial or religious use.
- Did the 2023 TGA rescheduling legalise DMT or ayahuasca?
- No. The February 2023 TGA decision rescheduled psilocybin and MDMA only — and only for use by Authorised Prescribers in tightly defined clinical settings. DMT was not included in that decision and remains Schedule 9 prohibited. No Authorised Prescriber pathway for DMT currently exists.
- What is the difference between DMT and ayahuasca chemically?
- DMT (N,N-Dimethyltryptamine) is the primary psychoactive compound in ayahuasca. Ayahuasca is a brewed preparation that combines a DMT-containing plant source with plants containing beta-carboline alkaloids, which inhibit the enzymes that would otherwise break down orally ingested DMT. This combination allows DMT to be absorbed through the digestive system. Both the isolated compound and the preparation are prohibited under Australian law.
- Can Australian researchers legally study DMT?
- Research involving Schedule 9 substances requires both TGA approval and Human Research Ethics Committee (HREC) approval. It is possible for approved research institutions to conduct such studies under these strict conditions. This is a narrow, heavily governed research pathway — it does not imply any general public access to the substance.
- Are there serious health risks associated with ayahuasca use?
- Yes. The beta-carboline compounds in ayahuasca act as monoamine oxidase inhibitors (MAOIs), creating potentially serious or life-threatening interactions with serotonergic medications (including SSRIs and SNRIs) and certain foods. Acute psychological adverse reactions have also been documented in the scientific literature, including severe anxiety and psychotic episodes, particularly in individuals with relevant personal or family psychiatric histories.
Related reading
Psychedelics and Drug Interactions (Educational)Psilocybin remains Schedule 9 prohibited in Australia outside narrow AP pathways. Here's what the research says about psychedelics and drug interactions.
Placebo Challenges in Psychedelic ResearchPlacebo controls are the backbone of clinical research — but in psychedelic trials, participants almost always know when they've taken the real thing. Here's why that matters.
The Global Regulatory Landscape for PsychedelicsThe global regulatory landscape for psychedelics compared: how Australia's Schedule 9 position sits against the US, Canada, the Netherlands and Portugal.
The Default Mode Network and PsychedelicsThe default mode network quietens during psilocybin exposure — here's what the neuroscience actually shows, and what Australian law says about it.
Ketamine in Medicine: Regulatory and Clinical ContextKetamine sits in a legally complex space in Australia — Schedule 8 controlled drug in medicine, with a growing research profile. Here's what the regulation actually says.
The Difference Between Decriminalisation and LegalisationDecriminalisation and legalisation mean very different things under Australian law. Here's what those terms actually describe — and why the distinction matters.
I write our psychedelic-science and regulation pieces, which means being very precise about what the law actually allows. Trained in neuroscience comms. I play jazz piano poorly but happily, lose at chess online, and read too many papers.
BSc Neuroscience
More from Daniel Okoro
The 2023 Australian Down-Scheduling of PsilocybinAustralia's 2023 psilocybin rescheduling created a narrow legal pathway under the TGA. Here's what actually changed — and what didn't.- Psychedelics and Drug Interactions (Educational)Psilocybin remains Schedule 9 prohibited in Australia outside narrow AP pathways. Here's what the research says about psychedelics and drug interactions.
Psychedelic-Assisted Therapy: The Supervised Clinical ModelPsilocybin remains a Schedule 9 prohibited substance in Australia outside a narrow clinical pathway. Here's what the supervised model actually looks like.
MDMA-Assisted Therapy and Its Australian Regulatory StatusMDMA sits at Schedule 8 in Australia under a narrow 2023 TGA ruling. Here's what that actually means legally, and what the research says.- Ketamine in Medicine: Regulatory and Clinical ContextKetamine sits in a legally complex space in Australia — Schedule 8 controlled drug in medicine, with a growing research profile. Here's what the regulation actually says.
The Authorised Prescriber Pathway for PsilocybinPsilocybin remains Schedule 9 prohibited in Australia — but the Authorised Prescriber pathway created a narrow legal route in 2023. Here's how it works.